Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03024203
Other study ID # PSYC-173-16
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2016
Est. completion date March 2018

Study information

Verified date November 2018
Source Queen's University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cognitive remediation (CR) is the best treatment to improve neurocognitive abilities for individuals with psychosis, however, there is no gold standard method of cognitive remediation available. Cognitive training refers to the training component of CR in which people practice computerized exercises that train specific cognitive abilities. There is no agreed upon approach within the field as to the type of training that is most effective with some studies, training higher level cognitive abilities, some training perceptual abilities, and others training general cognitive skills. This study will directly compare two competing methods of cognitive training on measures of neurophysiology, neurocognition, functional competence, and real-world functional performance.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date March 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- psychotic disorder

- No previous cognitive remediation in past 6 months

Exclusion Criteria:

- Brain injury

- Substance abuse

- Neurocognitive disorder

- Developmental Disability

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Remediation - Executive Training
Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
Cognitive Remediation - Perceptual Training
Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.

Locations

Country Name City State
Canada Queen's University Kingston Ontario

Sponsors (1)

Lead Sponsor Collaborator
Queen's University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Functional Performance - Specific Levels of Functioning (SLOF) from Baseline Rating scale completed by participants' case managers that rates their ability to perform different everyday tasks Post-treatment (within 2 weeks following the end of treatment)
Secondary Change in Neurocognition - MATRICS Cognitive Consensus Battery (MCCB) from Baseline The MCCB is the gold standard cognitive assessment for schizophrenia research Post-treatment (within 2 weeks following the end of treatment)
Secondary Change in Neurophysiology - EEG from Baseline Alpha and Theta band synchronization, p300, mismatch negativity Post-treatment (within 2 weeks following the end of treatment)
Secondary Functional Competence - Canadian Objective Assessment of Life Skills Brief (COALS-B) from Baseline Performance based measure of real life functional skills using role-play Post-treatment (within 2 weeks following the end of treatment)
Secondary Change in Functional Performance - Specific Levels of Functioning (SLOF) from Baseline Rating scale completed by participants' case managers that rates their ability to perform different everyday tasks Follow-Up (3 months after the end of treatment)
Secondary Change in Neurocognition - MATRICS Cognitive Consensus Battery (MCCB) from Baseline The MCCB is the gold standard cognitive assessment for schizophrenia research Follow-Up (3 months after the end of treatment)
Secondary Change in Neurophysiology - EEG from Baseline Alpha and Theta band synchronization, p300, mismatch negativity Follow-Up (3 months after the end of treatment)
Secondary Functional Competence - Canadian Objective Assessment of Life Skills Brief (COALS-B) from Baseline Performance based measure of real life functional skills using role-play Follow-Up (3 months after the end of treatment)
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00253240 - Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population